Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML
Top Cited Papers
Open Access
- 19 December 2006
- journal article
- Published by American Society of Hematology in Blood
- Vol. 109 (8) , 3509-3512
- https://doi.org/10.1182/blood-2006-06-030833
Abstract
The mTOR complex 2 (mTORC2) containing mTOR and rictor is thought to be rapamycin insensitive and was recently shown to regulate the prosurvival kinaKeywords
This publication has 14 references indexed in Scilit:
- Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic MalignanciesClinical Cancer Research, 2006
- mTOR and cancer: reason for dancing at the crossroads?Current Opinion in Genetics & Development, 2006
- Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR ComplexScience, 2005
- mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathwaysNature Medicine, 2004
- Nuclear factor‐KappaB modulation as a therapeutic approach in hematologic malignanciesCancer, 2004
- Mammalian target of rapamycin inhibition as therapy for hematologic malignanciesCancer, 2004
- A novel mechanism of gene regulation and tumor suppression by the transcription factor FKHRPublished by Elsevier ,2002
- Raptor, a Binding Partner of Target of Rapamycin (TOR), Mediates TOR ActionCell, 2002
- Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemiaBlood, 2002
- Mutational analysis of the tumour suppressor gene MMAC1/PTEN in malignant myeloid disordersEuropean Journal of Haematology, 2000